000118626 001__ 118626
000118626 005__ 20230519145534.0
000118626 0247_ $$2doi$$a10.2147/PGPM.S274741
000118626 0248_ $$2sideral$$a126472
000118626 037__ $$aART-2021-126472
000118626 041__ $$aeng
000118626 100__ $$aFernandes, MR
000118626 245__ $$aGenetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon
000118626 260__ $$c2021
000118626 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118626 5203_ $$aIntroduction: The genetic admixture of the Brazilian population has considerable relevance to the implementation of the principles of pharmacogenomics (PGx), as it may compromise the extrapolation of data obtained in more homogeneous world populations. Purpose: This study aims to investigate a panel of 117 polymorphisms in 35 pharmacogenes, which contains label recommendations or clinical evidence by international drug regulatory agencies, in Amazonian Native American populations, and compare the results obtained with continental population data from the 1000 Genomes Project Consortium. Patients and Methods: The study population is composed of 109 Native American individuals from three Brazilian Amazon groups. The genotyping of the PGx polymorphisms was performed by allelic discrimination using TagMan (R) OpenArray Genotyping with a panel of 120 customized assays on the QuantStudio (TM) 12K Flex Real-Time PCR System. Results: Statistical differences within the Native American populations were observed regarding both genotypes and phenotypes of some genes of the CYP family. The discriminant analysis of principal components (DAPC5) between the NAM group and the continental populations of the 1000 Genomes Project resulted in the clustering of the three Native American populations. Additionally, in general, the NAM group was determined to be closely situated between East Asia, America, and South Asia groups, which enabled us to infer a genetic similarity between these populations. The DAPC analysis further demonstrated that eight polymorphisms and six polymorphisms were more relevant in differentiating the NAM from the continental populations and the NAM populations among themselves, respectively. Conclusion: Some investigated polymorphisms show differences among world populations, particularly with populations of European origin, for whom precision medicine protocols are primarily designed. The accumulated knowledge regarding these variations may assist in the design of specific protocols for Native American populations and populations admixed with them.
000118626 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000118626 590__ $$a2.606$$b2021
000118626 591__ $$aPHARMACOLOGY & PHARMACY$$b197 / 279 = 0.706$$c2021$$dQ3$$eT3
000118626 592__ $$a0.683$$b2021
000118626 593__ $$aPharmacology$$c2021$$dQ2
000118626 593__ $$aMolecular Medicine$$c2021$$dQ2
000118626 594__ $$a3.0$$b2021
000118626 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118626 700__ $$aRodrigues, JCG
000118626 700__ $$aMaronas, O
000118626 700__ $$0(orcid)0000-0002-4703-6620$$aLatorre-Pellicer, A$$uUniversidad de Zaragoza
000118626 700__ $$aCruz, R
000118626 700__ $$aGuerreiro, JF
000118626 700__ $$aBurbano, RMR
000118626 700__ $$ade Assumpcao, PP
000118626 700__ $$aRibeiro-dos-Santos, A
000118626 700__ $$ados Santos, SEB
000118626 700__ $$aCarracedo, A
000118626 700__ $$ados Santos, NPC
000118626 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000118626 773__ $$g14 (2021), 117-133$$pPharm.genomics pers. med$$tPharmacogenomics and Personalized Medicine$$x1178-7066
000118626 8564_ $$s5075520$$uhttps://zaguan.unizar.es/record/118626/files/texto_completo.pdf$$yVersión publicada
000118626 8564_ $$s2826225$$uhttps://zaguan.unizar.es/record/118626/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118626 909CO $$ooai:zaguan.unizar.es:118626$$particulos$$pdriver
000118626 951__ $$a2023-05-18-15:33:32
000118626 980__ $$aARTICLE